§ Claim under review · Health
In laboratory studies, compounds found in mastic gum, a natural tree resin, suppressed the growth of 6 types of cancer cells: colon, prostate, pancreatic, bile duct, gastric (stomach), and lung. In some experiments, mastic gum triggered apoptosis while interfering with growth and division. Researchers found mastic gum could increase Bax, reduce Bcl-2, activate caspase-3 and caspase-9, and arrest the cell cycle. One colon study reported strong reduction in cancer-cell viability while normal human colon fibroblasts were not adversely affected. Other preclinical studies reported growth-inhibiting effects in prostate, pancreatic, bile duct, stomach, and lung cancer models.
Verdict
Mostly accurate
Confidence
HighSummary
The post accurately describes what is in the peer-reviewed preclinical literature on mastic gum. Real cell-culture and animal studies have reported that mastic gum extracts inhibit the growth of colon, prostate, pancreatic, bile duct, gastric, and lung cancer cells, and induce apoptosis through mechanisms including increased Bax, decreased Bcl-2, activation of caspase-3 and caspase-9, and cell cycle arrest. One study did report that normal human colon fibroblasts remained viable while colon cancer cells were killed under the same conditions. Important context the post is careful about but readers should still note: all of this evidence is preclinical, meaning it comes from cells in dishes and mice, not from human patients. There are no clinical trials showing that eating or chewing mastic gum treats or prevents cancer in people, and the doses used in laboratory experiments cannot be directly translated to a human diet.
The readings
key figures from the evidence72h IC50 of mastic gum resin against bile duct cancer (KMBC)
72h IC50 of mastic gum resin against colonic adenocarcinoma cells
Why this verdict
Evidence
Multiple peer-reviewed preclinical studies support each element of this claim.
The mastic gum resin suppressed proliferation of human cancer cells with 72 h IC50 value of 15.34 ± 0.21, 11.52 ± 0.18, 8.11 ± 0.23 and 5.2 ± 0.8 μg/mL for bile duct cancer (cholangiocarcinoma) (KMBC), pancreatic carcinoma (PANC-1), gastric adenocarcinoma (CRL-1739), and colonic adenocarcinoma cells. That same study specifically reported the selective effect on normal cells: after treatment with MGR, normal human colon fibroblast CCD-18Co cells remained viable, normal in size and morphology, and with the regular cell membrane .
For colon cancer, an earlier study using Chios mastic reported that a hexane extract of the plant product Chios mastic gum (He-CMG) is demonstrated to kill human colon cancer cells in vitro via the process of anoikis. Specifically, the sequence of events includes He-CMG-induced GI-arrest of the cells, detachment from the substrate, followed by apoptosis.
For prostate cancer, in vitro studies also suggested that mastic may have the ability to protect human LDL from oxidation and to induce the apoptosis of human colon cancer HCT116 cells , and separate work has shown gum mastic inhibits the androgen receptor in prostate cancer cells.
For pancreatic cancer, in vitro, gum mastic has been proven to inhibit growth of prostate cancer cells and induce apoptosis of colon cancer cells. In this study, we evaluated the effects of gum mastic in pancreatic cancer cells. We found that gum mastic, in vitro, had antiproliferative and apoptotic effects on human pancreatic cancer cells.
For lung cancer, evidence is primarily from mouse Lewis lung carcinoma. Specifically, CMO inhibited Lewis Lung Carcinoma tumor growth both in vitro and in vivo as well as the growth and survival of human K562 Leukemia Cells. Moulos and colleagues presented evidence concerning the molecular basis of CMO- induced anti-tumor effects.
For the Bax/Bcl-2/caspase mechanistic claims, a co-treatment study on tongue cancer cells reported that co-treatment of with eugenol and CGM on SCC25 cells showed several lines of apoptotic manifestation such as nuclear condensations, DNA fragmentation, the increase and decrease of Bax and Bcl-2, decrease of DNA content, the release of cytochrome c into cytosol, translocation of AIF , consistent with the pro-apoptotic mechanisms described in the claim.
Findings
✓ What's accurate 4
- Peer-reviewed in vitro studies exist for each of the six cancer types listed: colon, prostate, pancreatic, bile duct, gastric, and lung.
- Mechanisms described (apoptosis induction, Bax upregulation, Bcl-2 downregulation, caspase-3 and caspase-9 activation, cell cycle arrest) are all reported in the published literature for mastic gum or its components.
- The selective effect on colon cancer versus normal colon fibroblasts (CCD-18Co) is accurately reported in the Kurdish mastic resin paper.
- The claim's use of qualifiers ("in laboratory studies," "in some experiments," "preclinical," "cancer models") is appropriate and matches the evidence.
≈ What's misleading 2
- Minor conflation: the specific colon-vs-fibroblast selectivity result comes from Pistacia atlantica ssp. kurdica, a different subspecies from the more widely known Chios mastic (Pistacia lentiscus). The post says "mastic gum" generically, which is technically accurate but obscures that not all data comes from the same product.
- The phrase "6 types of cancer cells" could imply human cell-line evidence exists for all six. Human cell lines were used for colon, prostate, pancreatic, bile duct, and gastric, but the lung evidence is dominated by a mouse Lewis lung carcinoma model rather than human lung cancer cell lines. The post partially handles this by saying "cancer models" for the second listing.
? What's uncertain 2
- Whether any of these preclinical effects translate to clinical benefit in humans consuming mastic gum orally. No human cancer trials are cited or known.
- Whether serum concentrations achievable through normal dietary intake of mastic gum approach the IC50 values reported in cell culture.
Sources
7 of 7 linked to recordsTayoub et al., "Phytochemical analysis and antioxidant and anticancer activities of mastic gum resin from Pistacia atlantica subspecies kurdica," OncoTargets and Therapy, 2018
Balan et al., "Induction of apoptosis in human colon cancer HCT116 cells treated with an extract of the plant product, Chios mastic gum," In Vivo, 2005
He et al., "Gum mastic inhibits the expression and function of the androgen receptor in prostate cancer cells," Cancer, 2006
Huang et al., "Gemcitabine combined with gum mastic causes potent growth inhibition and apoptosis of pancreatic cancer cells," 2014
Moulos et al., "A transcriptomic computational analysis of mastic oil-treated Lewis lung carcinomas...," 2009
Paraschos et al., "Chios Mastic Gum: A Plant-produced Resin Exhibiting Numerous Diverse Pharmaceutical and Biomedical Properties," In Vivo, 2012
Papada & Kaliora, "Overview of Chios Mastic Gum Effects on Human Health," 2022